Literature DB >> 11745452

Comprehensive allelotype study of ovarian tumors of low malignant potential: potential differences in pathways between tumors with and without genetic predisposition to invasive carcinoma.

K Nakayama1, Y Takebayashi, T Namiki, N Tamahashi, S Nakayama, T Uchida, K Miyazaki, M Fukumoto.   

Abstract

Ovarian tumors of low malignant potential (LMP) are intermediate between adenomas and ovarian carcinomas (OC); however, the relevance of LMP to ovarian carcinogenesis is not clear. We performed a comparative analysis of allelotypes in 50 cases of LMP (42 mucinous and 8 serous) and 23 cases of OC (15 mucinous and 8 serous) to investigate any differences in genetic changes. Analysis of loss of heterozygosity (LOH) using 25 microsatellite markers reportedly associated with OC revealed that the total LOH frequency at each marker was significantly lower in LMP than in OC (p < 0.01). However, 9 (36%) loci showed higher LOH frequency in mucinous LMP than in mucinous OC. A genome-wide scan for LOH using 91 microsatellite markers and fine mapping revealed that LOH at D7S1805 (7q35) is characteristic of mucinous LMP (19.4% in mucinous LMP, 8.3% in mucinous OC). We further studied LOH in 3 cases of mucinous OC that were accompanied by mucinous LMP lesions. In 2 cases, LOH frequency was higher in the carcinoma portion than in the morphologically LMP portion. The other case showed microsatellite instability in the morphologically LMP portion and LOH in the carcinoma portion. Our results suggest the presence of an LMP-to-OC developmental sequence and the existence of a subset of LMP that does not develop into OC in the mucinous subtype of ovarian tumors. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11745452     DOI: 10.1002/ijc.1499

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.

Authors:  Sultana Razia; Kentaro Nakayama; Kohei Nakamura; Tomoka Ishibashi; Masako Ishikawa; Toshiko Minamoto; Kouji Iida; Yoshiro Otsuki; Satoru Nakayama; Noriyoshi Ishikawa; Satoru Kyo
Journal:  Exp Ther Med       Date:  2019-07-12       Impact factor: 2.447

2.  Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.

Authors:  Hiroki Sasamori; Kentaro Nakayama; Sultana Razia; Hitomi Yamashita; Tomoka Ishibashi; Masako Ishikawa; Seiya Sato; Satoru Nakayama; Yoshiro Otsuki; Ritsuto Fujiwaki; Noriyoshi Ishikawa; Satoru Kyo
Journal:  Curr Oncol       Date:  2022-05-18       Impact factor: 3.109

3.  EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.

Authors:  K Iida; K Nakayama; M T Rahman; M Rahman; M Ishikawa; A Katagiri; S Yeasmin; Y Otsuki; H Kobayashi; S Nakayama; K Miyazaki
Journal:  Br J Cancer       Date:  2011-07-05       Impact factor: 7.640

4.  Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin.

Authors:  V S Dhillon; A R Young; S A Husain; M Aslam
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

5.  Allelic loss at 19q12 and Xq11-12 predict an adverse clinical outcome in patients with mucinous ovarian tumours of low malignant potential.

Authors:  K Nakayama; Y Takebayashi; K Hata; R Fujiwaki; K Iida; M Fukumoto; K Miyazaki
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.